Search Technologies

Showing 1-2 of 2 results found

Substrate Reduction Therapy for Smith-Lemli-Opitz Syndrome and Related Disorders

The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) is seeking parties interested in co-development or licensing a substrate reduction therapy for Smith-Lemli-Opitz Syndrome (SLOS) and other diseases which have a secondary Niemann-Pick type C disease like cellular phenotype.

Therapeutics

Monomeric and Oligomeric Compounds as Contraceptives and Endocrine Therapeutics

The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) seeks research co-development partners and/or licensees for development of a new chemical entity and monomeric and oligomeric compound embodiments for development as a male contraceptive.

Therapeutics

You are here

Product Type

Development Stage

Therapeutic Area

Institutes and Centers

Search Technologies

Substrate Reduction Therapy for Smith-Lemli-Opitz Syndrome and Related Disorders

Monomeric and Oligomeric Compounds as Contraceptives and Endocrine Therapeutics